X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Dishman Pharma with Merck Ltd - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DISHMAN PHARMA vs MERCK LTD - Comparison Results

DISHMAN PHARMA    Change

Dishman Pharmaceuticals is involved in the manufacture of APIs (active pharmaceutical ingredients), intermediates, quaternary compounds and fine chemicals. Besides this, the company is a significant player in the CRAMS (Contract Research and Manufact... More

MERCK LTD 
   Change

Merck, the Indian arm of Merck KgaA (Germany), is a relatively smaller player among MNC pharma majors in the country. Merck has two business segments namely Pharmaceuticals and Chemicals. The pharmaceutical business, accounting for 68% of total sales... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DISHMAN PHARMA MERCK LTD DISHMAN PHARMA/
MERCK LTD
 
P/E (TTM) x 25.1 50.9 49.3% View Chart
P/BV x 3.3 7.7 43.5% View Chart
Dividend Yield % 0.7 0.4 180.7%  

Financials

 DISHMAN PHARMA   MERCK LTD
EQUITY SHARE DATA
    DISHMAN PHARMA
Mar-16
MERCK LTD
Dec-16
DISHMAN PHARMA/
MERCK LTD
5-Yr Chart
Click to enlarge
High Rs3741,060 35.3%   
Low Rs129623 20.7%   
Sales per share (Unadj.) Rs197.8632.4 31.3%  
Earnings per share (Unadj.) Rs21.245.7 46.4%  
Cash flow per share (Unadj.) Rs34.762.3 55.7%  
Dividends per share (Unadj.) Rs2.0011.00 18.2%  
Dividend yield (eoy) %0.81.3 60.8%  
Book value per share (Unadj.) Rs179.9388.8 46.3%  
Shares outstanding (eoy) m80.6916.60 486.1%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x1.31.3 95.6%   
Avg P/E ratio x11.918.4 64.5%  
P/CF ratio (eoy) x7.213.5 53.7%  
Price / Book Value ratio x1.42.2 64.6%  
Dividend payout %9.424.1 39.2%   
Avg Mkt Cap Rs m20,30613,969 145.4%   
No. of employees `0000.81.6 52.4%   
Total wages/salary Rs m5,3551,487 360.2%   
Avg. sales/employee Rs Th19,252.76,631.9 290.3%   
Avg. wages/employee Rs Th6,459.5939.2 687.8%   
Avg. net profit/employee Rs Th2,064.1479.4 430.5%   
INCOME DATA
Net Sales Rs m15,96110,498 152.0%  
Other income Rs m265242 109.5%   
Total revenues Rs m16,22610,741 151.1%   
Gross profit Rs m4,1031,135 361.4%  
Depreciation Rs m1,091276 395.9%   
Interest Rs m9440-   
Profit before tax Rs m2,3341,102 211.7%   
Minority Interest Rs m00-   
Prior Period Items Rs m10-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m624343 181.6%   
Profit after tax Rs m1,711759 225.5%  
Gross profit margin %25.710.8 237.7%  
Effective tax rate %26.731.1 85.8%   
Net profit margin %10.77.2 148.3%  
BALANCE SHEET DATA
Current assets Rs m11,0186,410 171.9%   
Current liabilities Rs m9,5178,828 107.8%   
Net working cap to sales %9.4-23.0 -40.8%  
Current ratio x1.20.7 159.5%  
Inventory Days Days11058 191.6%  
Debtors Days Days3538 90.8%  
Net fixed assets Rs m16,3041,406 1,159.3%   
Share capital Rs m161166 97.2%   
"Free" reserves Rs m12,9076,286 205.3%   
Net worth Rs m14,5166,455 224.9%   
Long term debt Rs m4,1890-   
Total assets Rs m29,8058,828 337.6%  
Interest coverage x3.5NM-  
Debt to equity ratio x0.30-  
Sales to assets ratio x0.51.2 45.0%   
Return on assets %8.98.6 103.6%  
Return on equity %11.811.8 100.3%  
Return on capital %17.517.1 102.7%  
Exports to sales %24.88.3 299.3%   
Imports to sales %3.721.0 17.8%   
Exports (fob) Rs m3,956869 455.0%   
Imports (cif) Rs m5962,209 27.0%   
Fx inflow Rs m4,952959 516.4%   
Fx outflow Rs m6972,612 26.7%   
Net fx Rs m4,255-1,653 -257.4%   
CASH FLOW
From Operations Rs m2,7861,070 260.3%  
From Investments Rs m-1,529-750 203.9%  
From Financial Activity Rs m-941-150 628.2%  
Net Cashflow Rs m316171 185.1%  

Share Holding

Indian Promoters % 61.4 0.0 -  
Foreign collaborators % 0.0 51.8 -  
Indian inst/Mut Fund % 3.7 18.2 20.3%  
FIIs % 12.7 1.0 1,270.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 22.1 29.1 75.9%  
Shareholders   46,261 28,591 161.8%  
Pledged promoter(s) holding % 35.8 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DISHMAN PHARMA With:   ASTRAZENECA PHARMA  DR. DATSONS LABS  CADILA HEALTHCARE  VENUS REMEDIES  CIPLA  

Compare DISHMAN PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Slumps Over 275 Points; Realty and Banking Stocks Witness Selling(Closing)

After trading on a volatile note throughout the day, share markets in India witnessed selling pressure during the closing hours and ended the day in red.

Related Views on News

MERCK LTD Announces Quarterly Results (1QFY19); Net Profit Up 63.1% (Quarterly Result Update)

Aug 8, 2018 | Updated on Aug 8, 2018

For the quarter ended June 2018, MERCK LTD has posted a net profit of Rs 328 m (up 63.1% YoY). Sales on the other hand came in at Rs 2 bn (down 17.1% YoY). Read on for a complete analysis of MERCK LTD's quarterly results.

MERCK LTD Announces Quarterly Results (4QFY18); Net Profit Up 53.2% (Quarterly Result Update)

Jul 20, 2018 | Updated on Jul 20, 2018

For the quarter ended March 2018, MERCK LTD has posted a net profit of Rs 227 m (up 53.2% YoY). Sales on the other hand came in at Rs 3 bn (up 27.1% YoY). Read on for a complete analysis of MERCK LTD's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

Is It the Right Time to Buy Pharma Stocks Now?(The 5 Minute Wrapup)

Sep 12, 2018

Is the pharma sector poised for a comeback? Is the worst over? I believe so.

Want Bigger Returns Than You Thought Possible? This is Where You Should Look(Profit Hunter)

Sep 12, 2018

Richa has discovered the single most profitable opportunity in the market - read on to discover more...

Are You Blindly Investing In Equities? Read This...(Outside View)

Sep 11, 2018

PersonalFN explains how blindly investing in equities can prove hazardous to your wealth and health.

Investors Are Redeeming From Equity Mutual Funds Now. Should You?(Outside View)

Sep 12, 2018

PersonalFN elucidates if you should redeem from equity mutual fund now, and the approach to follow before you decide to sell mutual funds.

Outperformance of Strong Established Brands in the Indian Stock market(Chart Of The Day)

Sep 14, 2018

Strong Well established Indian Brands have comfortably outperformed the index in the decade post the global financial crisis.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

DISHMAN PHARMA SHARE PRICE


May 29, 2017 (Close)

TRACK DISHMAN PHARMA

  • Track your investment in DISHMAN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DISHMAN PHARMA

DISHMAN PHARMA - NATCO PHARMA COMPARISON

COMPARE DISHMAN PHARMA WITH

MARKET STATS